Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Glendale, California 91206


Purpose:

The purpose of this study is to find out the time it takes to absorb, distribute, breakdown and remove the drug from the body, safety and tolerability of AMG 581 in healthy participants and subjects with schizophrenia.


Study summary:

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetic profile of single-ascending oral doses of AMG 581 in healthy subjects and subjects diagnosed with schizophrenia or schizoaffective disorder receiving antipsychotic treatment. This will be a placebo-controlled, single-ascending oral-dose study of AMG 581 with a food-effect cohort. Approximately 70 subjects will be enrolled. This study will enroll healthy subjects into 8 cohorts (Cohorts 1,2,3,4,5,6,8 and 9), and subjects with schizophrenia or schizoaffective disorder receiving antipsychotic medication into a single cohort (Cohort 7).


Criteria:

Inclusion Criteria: - Provide informed consent prior to initiation of any study-related procedure - Male and female subjects ≥ 18 to ≤ 45 years of age at the time of screening - Non-nicotine or non-tobacco for healthy subjects - No history of relevant medical disorders - BMI ≥ 18.0 and ≤ 30.0 - Non-reproductive females - Males practicing effect birth control - Avoid tanning/direct sunlight - Willing to consume high-fat meal - Schizophrenia or schizoaffective disorder - PANSS score ≤ 4 points on a few items (i.e. conceptual disorganization, hallucinatory behavior, excitement, suspiciousness/persecution, hostility, depression, anxiety, disorientation, uncooperativeness, disturbance of volition, and poor impulse control) / total score ≤ 80 points Exclusion Criteria: - Females lactating/breastfeeding - Pregnant partners of male subjects - Tremor or gait disturbance - History of hereditary shorten QT syndrome - Malignancy or tumor (other than skin cancers) - History of GI disease - QTc ≥ 450 msec or ≤ 380 msec - Creatinine clearance < 80 mL/min at screening


NCT ID:

NCT02567370


Primary Contact:

Study Director
MD
Amgen


Backup Contact:

N/A


Location Contact:

Glendale, California 91206
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.